Osivax

Companies & groups

Osivax is a European clinical-stage biotechnology company pioneering universal influenza vaccine development through a groundbreaking T-cell-targeted approach.
Our flagship vaccine candidate, OVX836, represents a paradigm shift in influenza prevention by targeting the highly conserved nucleoprotein across all influenza A strains, including pandemic variants. We have completed 7 clinical trials including 5 in Europe, with an additional large-scale Phase 2b efficacy trial currently ongoing across 16 clinical sites in France, Belgium, Germany, and Finland which is set to include 2850 participants by the end of 2025.
Osivax is headquartered in Lyon, France, with an additional operational site in Liège, Belgium, we employ approximately 50 highly qualified professionals specialized in R&D, CMC, clinical development, regulatory affairs, and quality management.

6511761101113-89

PARIS

FR

business_company

SAS